Wendy A Woodward
Overview
Explore the profile of Wendy A Woodward including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
274
Citations
6495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bendre S, Wang Y, Hajyousif B, Rajendra K, K C R, Bhogale S, et al.
bioRxiv
. 2025 Mar;
PMID: 40027727
Although immune therapy has seen significant advances, the majority of breast and other solid tumors do not respond or quickly develop resistance. One factor driving resistance is highly immune suppressive...
2.
3.
Wang X, Zhao L, Song X, Wu X, Krishnamurthy S, Semba T, et al.
NPJ Precis Oncol
. 2024 Nov;
8(1):265.
PMID: 39558017
Triple-negative inflammatory breast cancer (TN-IBC) is the most aggressive type of breast cancer, yet its defining genomic, molecular, and immunological features remain largely unknown. In this study, we performed the...
4.
Jacomina L, Swanson D, Mitchell M, Woodward W, Smith B, Hoffman K, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
PMID: 39549757
Purpose: Symptomatic locoregionally advanced breast cancer (SLABC) can cause troublesome pain or wound complications that negatively impact quality of life. Although palliative radiation therapy (RT) can minimize tumor-related symptoms, how...
5.
Reddy J, Sherry A, Fellman B, Liu S, Bathala T, Haymaker C, et al.
Int J Radiat Oncol Biol Phys
. 2024 Nov;
121(4):885-893.
PMID: 39486645
Purpose: Prior evidence suggests a progression-free survival (PFS) benefit from adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy for patients with some oligometastatic solid tumors. Randomized trials testing this...
6.
Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicolo E, et al.
Eur J Cancer
. 2024 Nov;
213:115097.
PMID: 39486164
Background: Inflammatory breast cancer (IBC) is the most aggressive clinical presentation of breast cancer, recapitulating a specific biology with more immune-vulnerability than non-IBC. Patients with metastatic, triple-negative IBC (mTN-IBC) receive...
7.
Shaitelman S, Le-Petross H, Raso M, Swanson D, Schalck A, Contreras A, et al.
Int J Radiat Oncol Biol Phys
. 2024 Aug;
121(1):90-96.
PMID: 39147206
Purpose: Radiation therapy is an underinvestigated tool for priming the immune system in intact human breast cancers. We sought here to investigate if a preoperative radiation therapy boost delivered was...
8.
Glencer A, Wanis K, Brown S, Lucci A, Sun S, Adesoye T, et al.
Ann Surg Oncol
. 2024 Jul;
31(11):7326-7334.
PMID: 39034365
Background: Inflammatory breast cancer (IBC) is rare and biologically aggressive. We sought to assess diagnostic and management strategies among the American Society of Breast Surgeons (ASBrS) membership. Patients And Methods:...
9.
Kumar S, Larson R, Stecklein S, Reddy J, Debeb B, Amos R, et al.
bioRxiv
. 2024 Jun;
PMID: 38854130
Purpose: Inhibiting HMG-CoA reductase with simvastatin prevents breast cancer metastases in preclinical models and radiosensitizes monolayer and stem-like IBC cell lines . Given the extensive use of simvastatin worldwide and...
10.
Fu J, Manne R, Ngo-Huang A, Tennison J, Ng A, Andersen C, et al.
BMJ Support Palliat Care
. 2024 Jun;
PMID: 38839248
Objectives: The primary objective of this retrospective review is to describe patient-reported improvement in muscular pain after initial treatment with onabotulinum toxin. A secondary objective was to determine other physiatry...